1. Home
  2. OPFI vs RCEL Comparison

OPFI vs RCEL Comparison

Compare OPFI & RCEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo OppFi Inc.

OPFI

OppFi Inc.

N/A

Current Price

$5.54

Market Cap

480.6M

Sector

Finance

ML Signal

N/A

Logo Avita Medical Inc.

RCEL

Avita Medical Inc.

N/A

Current Price

$15.59

Market Cap

403.3M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
OPFI
RCEL
Founded
2009
N/A
Country
United States
United States
Employees
N/A
N/A
Industry
Finance: Consumer Services
Medical/Dental Instruments
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
480.6M
403.3M
IPO Year
2020
2018

Fundamental Metrics

Financial Performance
Metric
OPFI
RCEL
Price
$5.54
$15.59
Analyst Decision
Buy
Strong Buy
Analyst Count
3
3
Target Price
$10.53
★ $20.63
AVG Volume (30 Days)
★ 901.2K
557.4K
Earning Date
10-28-2026
11-05-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 175.00
27.20
EPS
★ 1.14
N/A
Revenue
N/A
★ $71,610,000.00
Revenue This Year
$76.65
$33.70
Revenue Next Year
$7.68
$23.47
P/E Ratio
$5.05
★ N/A
Revenue Growth
N/A
★ 11.45
52 Week Low
$5.36
$3.22
52 Week High
$11.69
$18.43

Technical Indicators

Market Signals
Indicator
OPFI
RCEL
Relative Strength Index (RSI) 39.23 52.64
Support Level $5.36 $14.67
Resistance Level $6.19 $16.90
Average True Range (ATR) 0.23 1.37
MACD -0.02 -0.22
Stochastic Oscillator 6.06 28.46

Price Performance

Historical Comparison
OPFI
RCEL

About OPFI OppFi Inc.

OppFi Inc. is a tech-enabled, mission-driven specialty finance platform that broadens the reach of community banks to expand credit access for everyday Americans. It recognizes revenue from finance charges on installment and SalaryTap contracts using the interest method.

About RCEL Avita Medical Inc.

Avita is largely a single product company. Its RECELL system is an innovative burn treatment device which creates Spray-on Skin from a small skin sample within 30 minutes, thus avoiding or reducing the need for skin grafts. It's approved for the treatment of adult and paediatric patients in the US and an expanded indication for soft-tissue reconstruction. It is currently used in most of the 140 US burn centers. Despite having product approval in Australia, Canada, and China, Avita is not actively marketing in those territories and focussing instead on the US region, although international sales, particularly in Japan, are growing. Avita is domiciled, and has its primary listing, in the US.

Share on Social Networks: